Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05536297 · ClinicalTrials.gov registry record · Phase 3
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
A Phase 3 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 278
- Enrollment target
NCT05536297 is a Phase 3 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 278 participants.
The verdict
NCT05536297, a Phase 3 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 278 participants
- Enrollment target
Study Summary
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study treatment (either avacincaptad pegol or Sham).
Interventions
- DRUG avacincaptad pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2022-09-26 |
| Est. Completion | 2025-04-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05536297
The ClinicalTrials.gov registry entry for NCT05536297 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which avacincaptad pegol is the first listed.
NCT05536297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05536297 about?
NCT05536297 is a clinical study titled "Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy". The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study treatment (either avacincaptad pegol or Sham).
What is the current status of trial NCT05536297?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 278 participants. The study started on 2022-09-26. Estimated completion is 2025-04-10.
What interventions are being tested in trial NCT05536297?
The interventions under investigation include: avacincaptad pegol (DRUG).
Who is sponsoring clinical trial NCT05536297?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.